Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV Cetirizine vs IV Diphenhydramine for Prevention of Infusion Reactions
NCT04189588Phase 2Completed
- Sponsor
- TerSera Therapeutics
- Start
- Mar 2020
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cetirizine in hypersensitivity infusion reaction (2 arms), sponsored by TerSera Therapeutics. Primary endpoint: Number of Hypersensitivity Reactions to Treatment With an Anti-CD20 Antibody or Paclitaxel. Started Mar 2020; status: completed.
02
Drugs
cetirizine
03
Conditions
hypersensitivity infusion reaction
Beyond the preview
Go deeper on NCT04189588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04189588.